Latest news with #Ganorkar
Time of India
26-06-2025
- Business
- Time of India
LITU alumnus Kirti Ganorkar is Sun Pharma's MD
1 2 3 Nagpur: Kirti Ganorkar, an alumnus of LIT University's batch of 1988, has been appointed as the managing director of Sun Pharmaceutical Industries Ltd. Ganorkar joined Sun Pharma in 1996 and has held various leadership roles across business development, marketing, M&A, new product introduction, project management, IP and litigation. He has played a pivotal role in driving Sun Pharma's foray into specialty by securing rights for key products such as Ilumya. Ganorkar led Sun Pharma's entry into Japan and laid initial groundwork for the company's Europe entry. He has impactfully led Sun Pharmaceutical's US business with stewardship of several notable generic programmes from concept to commercialisation. He has been heading the India Business at Sun Pharmaceuticals since June 2019. Under his leadership, Sun Pharma's India Business has grown consistently, further increasing its market share. Laxminarayan Innovation Technological University, since its inception as LIT in 1942, has given the global industry several towering stalwarts. The year 2025 has been a momentous one for LIT University alumni. Earlier this year, Subramanian Sarma, an LIT University alumnus of 1979 batch of chemical engineering was appointed as the deputy managing director of Larsen & Toubro (L&T). Each year, LIT University reinforces its position as one of the most premier institutes in chemical engineering and technology by producing such stalwarts.
New Indian Express
16-06-2025
- Business
- New Indian Express
FDA observations, leadership change keep Sun Pharma stock in spotlight on Monday
CHENNAI: Shares of Sun Pharmaceutical Industries Ltd. are under investor scrutiny today following two significant developments announced over the weekend — the US drug regulator's audit findings at a key manufacturing facility and a major leadership transition. The US Food and Drug Administration (USFDA) issued a Form-483 with eight observations concerning manufacturing practices at Sun Pharma's Halol facility in Gujarat. While the observations do not constitute regulatory action, they point to areas requiring corrective measures to meet FDA compliance standards. Sun Pharma has acknowledged the observations and committed to addressing them promptly. The inspection, conducted between June 2 and June 13, 2025, is especially significant as the Halol plant has been under an import alert since December 2022 due to previous regulatory violations. In a parallel development, the company announced the elevation of Kirti Ganorkar to the role of Managing Director, effective September 1, 2025. Ganorkar, who has headed Sun Pharma's India business since 2019, will take over full operational responsibilities, with all functions reporting directly to him. Founder Dilip Shanghvi will continue as Executive Chairman of the Board, ensuring strategic continuity. In light of these developments, investors are expected to closely monitor the company's stock performance in the coming days. Market analysts say the resolution of USFDA concerns at Halol and the smooth execution of the leadership transition will be key to shaping investor sentiment and the company's near-term outlook.
Time of India
14-06-2025
- Business
- Time of India
Kirti Ganorkar: Why the veteran insider is the right dose for Sun Pharma
Mumbai: For nearly thirty years, Kirti Ganorkar quietly stood at Sun Pharma as a rock, much like his astute boss Dilip Shanghvi , the founder of Sun Pharma. Steadfastly Shanghvi steered Sun Pharma from a small India-focused branded generic player to one that is rapidly emerging as a global specialty drugs company. From September 1, Kirti Ganorkar (58), a chemical engineer and a diehard cricket aficionado, will helm India's largest drugmaker as its managing director, while Shanghvi will continue in the role of executive chairman. In a June 13 statement, Sun Pharma said this marks the culmination of a structured and forward-looking succession planning process, underscoring the organisation's commitment to leadership continuity and strategic governance. For Ganorkar's elevation, the timing is crucial given the global scale of Sun Pharma's operations. It includes a growing and challenging business environment in the US, Europe and a range of emerging markets while keeping Sun Pharma at the top of the intensely competitive home market, India. For FY2025, Sun Pharma had sales of ₹52,041 crore, a 9% growth over the previous year, while its net profit stood at ₹11,984 crore, up 19%. Of which, Sun Pharma's global specialty products sales stood at $1.21 billion (₹10,334 crore), up 17.1%, and accounted for 19.7% of FY25 sales. Alone, Sun Pharma's India sales contribute over 32% of its global revenues. When Ganorkar made his move from German Remedies (acquired later by Zydus Lifesciences in 2001), a united entity for a group of German pharma companies and joined Sun Pharma in 1996 as an executive assistant to Shanghvi, the Indian pharma market was very different. Sun Pharma was at a fraction of its present size. The market was poised for a leap in sales of drugs for heart ailments, diabetes, neurology, and cancer, the segments that have been the primary focus for the company. Now, the dynamics have changed with almost every large Indian company showing prowess of deep reach and scientific expertise as they try to outclass others from in-licensing innovative products to launching their own. Industry experts, who follow Sun Pharma closely, say Ganorkar has a tough task ahead, but the established strength of the company comes as a big help. To succeed Dilip Shanghvi, known for his calculated yet bold moves, Ganorkar will need to combine all his experience. He has held diverse roles at Sun Pharma from business development, marketing, M&A, new product introductions, project management, to intellectual property litigation. An avid cricket follower, Ganorkar is the perfect all-rounder that Shanghvi has chosen. In the new innings, he must demonstrate the skills of MS Dhoni as a cool captain while showing the aggression of Virat Kohli. "Can he be good in the test match format and T20. That is the key," says a senior industry veteran, who was pleasantly surprised to see Ganorkar's new position. Economic Times WhatsApp channel )
United News of India
14-06-2025
- Business
- United News of India
Sun Pharma appoints Kirti Ganorkar as new MD
Mumbai, June 14 (UNI) Pharma major Sun Pharmaceutical Industries said that it has appointed Kirti Ganorkar as the Managing Director of the company effective September 1, 2025, succeeding Dilip Shanghvi to the job. The entire business and all functions will be reporting to Ganorkar. This appointment is subject to approval of the shareholders at the upcoming annual general meeting, the company release said. The announcement marks the culmination of a structured and forward-looking succession planning process at Sun Pharma, underscoring the organisation's commitment to leadership continuity and strategic governance. Ganorkar has been heading India Business at Sun Pharma since June 2019. Under his leadership, the company's India Business has grown consistently, further increasing its market share. Previously, he has held various leadership roles across business development, marketing, M&A, new product introduction, project management, IP and litigation at the drug firm, it added. Ganorkar played a key role in driving Sun Pharma's foray into speciality by securing rights for innovative products such as Ilumya. He led the company's entry into Japan and laid the initial groundwork for the company's foray into Europe, it said. Ganorkar also supported the US business with stewardship of several notable generic projects from concept to commercialisation. As Executive Chairman, Shanghvi will continue to chair the Board. He will focus on strengthening Sun Pharma's speciality portfolio and provide insights towards shaping the company's long-term strategy, the release added. Dilip Shanghvi, Chairman & Managing Director of Sun Pharma, said, ''Kirti has consistently demonstrated effective leadership, managing diverse roles at Sun. "I have a firm belief in his ability to lead the company into its next phase of growth and extend my best wishes for his success." His elevation showcases our strong in-house talent pool, ensuring continuity of Sun Pharma's core value systems." UNI JS ARN
Time of India
14-06-2025
- Business
- Time of India
Sun Pharmaceutical Industries: Sun Pharma Announces Kirti Ganorkar as New Managing Director Amid Executive Restructuring, ETHRWorld
Advt Advt Join the community of 2M+ industry professionals. Subscribe to Newsletter to get latest insights & analysis in your inbox. All about ETHRWorld industry right on your smartphone! Download the ETHRWorld App and get the Realtime updates and Save your favourite articles. In a top-level rejig, Sun Pharmaceutical Industries on Friday said it has appointed Kirti Ganorkar as the Managing Director of the company effective September 1, 2025, succeeding Dilip Shanghvi to the business and all functions will be reporting to Ganorkar, the Mumbai-based drug major said in a Executive Chairman, Shanghvi will continue to chair the company's Board, it Gandhi - President & CEO, North America - has decided to pursue his interests outside Sun Pharma, the company Ascroft will be joining as CEO - North America, succeeding Gandhi, it appointment is subject to approval of the shareholders at the upcoming annual general meeting, it announcement marks the culmination of a structured and forward-looking succession planning process at Sun Pharma, underscoring the organisation's commitment to leadership continuity and strategic governance, the drug firm has been heading India Business at Sun Pharma since June his leadership, the company's India Business has grown consistently, further increasing its market share, the company he has held various leadership roles across business development, marketing, M&A, new product introduction, project management, IP and litigation at the drug firm, it played a key role in driving Sun Pharma's foray into speciality by securing rights for innovative products such as Ilumya, the drug firm led the company's entry into Japan and laid the initial groundwork for the company's foray into Europe, it also supported the US business with stewardship of several notable generic projects from concept to commercialisation, the company said.A chemical engineer and MBA, Ganorkar joined Sun Pharma in 1996."Kirti has consistently demonstrated effective leadership, managing diverse roles at Sun. I have a firm belief in his ability to lead the company into its next phase of growth and extend my best wishes for his success," Shaghvi elevation showcases our strong in-house talent pool, ensuring continuity of Sun Pharma's core value systems, he will focus on strengthening the company's speciality portfolio and provide insights towards shaping the company's long-term strategy, the company said. PTI
